ARTBIO Secures $132M Series B to Propel Alpha Radioligand Therapies and Expand Global Manufacturing

Cambridge, MA, July 29, 2025 (PRNewswire) -- ARTBIO raised $132 million in a Series B round led by Sofinnova Investments and B Capital to advance its alpha radioligand therapy pipeline, including its lead program AB001 for prostate cancer. The funding supports Phase II development, pipeline expansion, and a proprietary supply chain infrastructure to scale manufacturing globally. This investment reflects strong market confidence in ARTBIO’s innovative approach to targeted cancer therapies and supply chain integration.

Read full article here.